-
Azithromycin: An Evidence-First Assay Framework
2026-09-10
Azithromycin is a macrolide antibiotic whose value in research depends on more than a single MIC. This evidence-first guide connects ribosomal mechanism, formulation behavior, resistance testing, historical macrolide data, and trypanosomosis models to improve assay design and interpretation.
-
Ferroelectric Artificial Photoreceptor for Visual Adaptation
2026-09-09
Zhang and colleagues developed a ferroelectric-liquid metal hybrid film that converts visible and near-infrared light into electrical signals while reproducing key scotopic and photopic adaptation behaviors. Rodent experiments showed restored visible-light sensitivity, infrared perception, and stable in vivo integration, establishing a materials platform for broad-spectrum retinal prostheses.
-
FOXM1–ERα Biomarkers in Female Lung Adenocarcinoma
2026-09-09
This study integrates transcriptomic, survival, immune, and cell-based analyses to examine FOXM1 in female lung adenocarcinoma and proposes a DGCR5–hsa-miR-204-5p–FOXM1–ERα network. Its main practical value is the combination of computational biomarker discovery with FOXM1 knockdown experiments, while its mechanistic network and immunotherapy implications remain hypotheses requiring further validation.
-
Lovastatin and the Logic of Cell-State Exit
2026-09-08
Lovastatin is more than an HMG-CoA reductase inhibitor for routine viability testing. This article connects its metabolic effects with a plant meristem study to develop a more rigorous framework for interpreting proliferation, apoptosis, and macrophage efferocytosis assays.
-
CARDIO Reveals HSPB7 Rescue in Titin Cardiomyopathy
2026-09-08
Chopra and colleagues developed CARDIO, a high-content morphological profiling assay for human stem cell-derived cardiomyocytes, and used it to identify HSPB7 as a modifier of titin-associated cardiomyopathy. CRISPR knockout screening followed by engineered heart tissue validation showed that HSPB7 loss produced a hypertrophic phenotype while restoring contractile function in a titin disease model.
-
mCherry mRNA: A Delivery-Ready Reporter Benchmark
2026-09-07
Explore how Cap 1, 5mCTP, ψUTP, and poly(A) architecture shape mCherry mRNA performance. This article presents a practical framework for separating delivery, translation, and fluorescence in advanced reporter assays.
-
Amyloid Beta-peptide (25-35) Workflows
2026-09-05
Build reproducible acute neurotoxicity, mitochondrial stress, and microglial activation assays with Aβ25-35. This guide connects practical peptide handling to mechanism-focused readouts for Alzheimer’s disease neurotoxicity models, including the FLOT1–FOSL2–EphA2 pathway.
-
Indomethacin Workflows for Inflammation Research
2026-09-05
Indomethacin is a versatile nonsteroidal anti-inflammatory drug for separating cyclooxygenase, PPARγ, and membrane effects in cell-based assays. This practical guide connects those activities to SEMA3E-driven beige adipocyte research, with workflow controls and troubleshooting steps for more reproducible inflammation and lipid metabolism studies.
-
Phosphotungstic Acid Negative Stain Solution Guide
2026-09-04
Phosphotungstic Acid Negative Stain Solution (2%) is more than a contrast reagent: it is a practical structural quality-control step for virus imaging and macromolecular assays. This guide explains how to connect negative-stain observations with glycan-focused antiviral research without overstating what electron microscopy can prove.
-
Ciprofloxacin hydrochloride: Assay Workflows
2026-09-04
Ciprofloxacin hydrochloride supports controlled antibacterial, cell-viability, and host-response experiments through a mechanism centered on DNA replication stress. This guide translates its fluoroquinolone activity and emerging cross-domain evidence into practical assay design, formulation, and troubleshooting choices.
-
Latrunculin A: Actin Dynamics Workflow Guide
2026-09-03
Latrunculin A provides a rapid, reversible way to test whether actin remodeling drives cell shape, motility, or axon growth. This workflow connects acute cytoskeleton perturbation with the stiffness-sensitive DRG regeneration mechanism described in recent research, while separating actin dependence from Piezo1-specific effects.
-
Ivermectin and Assay Logic from GSDMC Biology
2026-09-03
Explore Ivermectin A2813 as a broad-spectrum anti-parasitic research compound through a mechanism-to-measurement framework informed by GSDMC cancer biology. Learn how to align parasite phenotyping, controls, orthogonal validation, and compound handling without overstating cross-domain evidence.
-
EdU Imaging Kits (HF594) for Drug-Response Biology
2026-09-02
EdU Imaging Kits (HF594) translate S-phase DNA synthesis into a sensitive endpoint for microscopy and flow cytometry. This article shows how to interpret EdU data in drug-resistance and pharmacodynamic studies without confusing proliferation with mechanism.
-
Making PD-L1 Biology Spatially Actionable
2026-09-02
A mechanism-led guide to using Biotin-tyramide and tyramide signal amplification to connect PD-L1 trafficking biology with spatially resolved translational evidence. The article examines how HRP-mediated deposition can strengthen IHC and ISH workflows while preserving appropriate controls and interpretive boundaries.
-
CIP2A, PKM2, and OXPHOS in NSCLC
2026-09-01
The reference study identifies CIP2A as a metabolic regulator that shifts PKM2 toward tetramer formation, mitochondrial localization, and oxidative phosphorylation in non-small cell lung cancer. Its integrated genetic, biochemical, metabolic, clinical, and in vivo evidence supports combined targeting of CIP2A and glycolysis as a testable strategy, while also defining important limits for translation.